Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics (Nasdaq: ABEO) has announced the granting of equity awards to nine new non-executive employees. The awards, approved under Nasdaq Listing Rule 5635(c)(4), consist of 44,700 restricted shares of Abeona common stock. The shares will vest in three equal annual installments, with full vesting occurring on the third anniversary of the Grant Date, contingent upon continued employment. The equity awards were approved by the Compensation Committee of Abeona's Board of Directors on November 30, 2024, as material inducement to employment.
Abeona Therapeutics (Nasdaq: ABEO) ha annunciato l'assegnazione di premi azionari a nove nuovi dipendenti non esecutivi. I premi, approvati ai sensi della Regola di Quotazione Nasdaq 5635(c)(4), consistono in 44.700 azioni equivalenti di azioni ordinarie di Abeona. Le azioni si matureranno in tre rate annuali uguali, con la piena maturazione che avverrà al terzo anniversario della Data di Assegnazione, a condizione che l'impiego continui. I premi azionari sono stati approvati dal Comitato per la Compensazione del Consiglio di Amministrazione di Abeona il 30 novembre 2024, come incentivo sostanziale all'assunzione.
Abeona Therapeutics (Nasdaq: ABEO) ha anunciado la concesión de premios de capital a nueve nuevos empleados no ejecutivos. Los premios, aprobados bajo la Regla de Cotización Nasdaq 5635(c)(4), consisten en 44,700 acciones restringidas de acciones ordinarias de Abeona. Las acciones se adquirirán en tres instalaciones anuales iguales, siendo la plena adquisición al tercer aniversario de la Fecha de Concesión, y condicionado a la continuidad del empleo. Los premios de capital fueron aprobados por el Comité de Compensación de la Junta Directiva de Abeona el 30 de noviembre de 2024, como un incentivo material para la contratación.
Abeona Therapeutics (Nasdaq: ABEO)는 새로운 비상임 직원 아홉 명에게 주식 보상을 부여했다고 발표했습니다. 해당 보상은 Nasdaq 상장 규칙 5635(c)(4) 아래 승인되었으며, 44,700주의 제한 주식으로 구성됩니다. 이 주식은 세 번의 동일한 연간 할당으로 분할되어 제공되며, Grant Date로부터 3주년이 되는 날에 완전한 귀속이 이루어질 예정이며, 이는 계속 고용되는 것을 전제로 합니다. 자본 보상은 Abeona 이사회 보상위원회에서 2024년 11월 30일에 승인되었으며, 고용 유인을 위한 중요한 인센티브로 제공됩니다.
Abeona Therapeutics (Nasdaq: ABEO) a annoncé l'octroi de récompenses en actions à neuf nouveaux employés non exécutifs. Les récompenses, approuvées en vertu de la Règle de cotation Nasdaq 5635(c)(4), consistent en 44 700 actions restreintes d'actions ordinaires d'Abeona. Les actions seront acquises par tranches annuelles égales sur trois ans, la pleine acquisition intervenant le troisième anniversaire de la date d'octroi, sous réserve de la poursuite de l'emploi. Les récompenses en actions ont été approuvées par le Comité de rémunération du Conseil d'administration d'Abeona le 30 novembre 2024, comme incitatif matériel à l'emploi.
Abeona Therapeutics (Nasdaq: ABEO) hat die Gewährung von Aktienoptionen an neun neue nicht-executive Mitarbeiter bekannt gegeben. Die Optionen, die unter der Nasdaq-Listing-Regel 5635(c)(4) genehmigt wurden, bestehen aus 44.700 eingeschränkten Aktien
- Successful attraction of new talent with equity-based compensation
- Three-year vesting schedule promotes employee retention
- Potential dilution of existing shareholders through new share issuance
CLEVELAND, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On November 30, 2024, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to nine individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 44,700 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of the FDA’s review of our BLA resubmission for pz-cel; the FDA’s grant of a Priority Review Voucher upon pz-cel approval; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
FAQ
How many restricted shares did Abeona Therapeutics (ABEO) grant to new employees in November 2024?
What is the vesting schedule for ABEO's November 2024 employee equity awards?
Under which Nasdaq rule did Abeona Therapeutics (ABEO) grant the November 2024 equity awards?
